Showing results (1211-1220 of 4,880) with videos related to

Sort By:
Pageof 488
Urologic Oncology|June 9, 2019
Trends and outcomes in contemporary management renal cell carcinoma and vena cava thrombusAlp Tuna Beksac, Qainat N Shah, David J Paulucci, et al.
Urologic Oncology|May 21, 2019
Urologic oncology workforce diversity: A first step in reducing cancer disparitiesTullika Garg, Ali Antar, Jennifer M Taylor
Urologic Oncology|May 8, 2019
The current state of randomized clinical trial evidence for prostate brachytherapyRobert T Dess, Payal D Soni, William C Jackson, et al.
Urologic Oncology|October 17, 2018
Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinomaFranziska Büscheck, Christoph Fraune, Ronald Simon, et al.
Urologic Oncology|July 25, 2016
Utility of novel androgen receptor therapies in the real world: A nuanced approachMallika Dhawan, Charles J Ryan
Urologic Oncology|July 31, 2016
Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studiesVinayak Muralidhar, Paul L Nguyen
Urologic Oncology|May 12, 2015
Genetic variations in genes involved in testosterone metabolism are associated with prostate cancer progression: A Spanish multicenter studyLuis Alberto Henríquez-Hernández, Almudena Valenciano, Palmira Foro-Arnalot, et al.
Urologic Oncology|April 23, 2015
Weaker ERG expression in patients with ERG-positive prostate cancer is associated with advanced disease and weaker androgen receptor expression: An Indian outlookMoushumi Suryavanshi, Anurag Mehta, Jiten Jaipuria, et al.
Urologic Oncology|May 5, 2015
Commentary on: "Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study." Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Hirmand M, Smith MR. Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium. Electronic address: bertrand.tombal@uclouvain.be. Aarhus University Hospital, Aarhus, Denmark. Herlev Hospital, Herlev, Denmark. AZ Groeninge Kortrijk, Kortrijk, Belgium. UZ Leuven, Leuven, Belgium. Klinik und Poliklinik für Urologie, RWTH University Aachen, Aachen, Germany. Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. UZ Brussel, Brussels, Belgium. Univerzita Karlova v Praze, Prague, Czech Republic. Astellas Pharma Global Development, Leiden, Netherlands. Astellas Pharma Global Development, Northbrook, IL, USA. Medivation Inc, San Francisco, CA, USA. Massachusetts General Hospital Cancer Center, Boston, MA, USA: Lancet Oncol. 2014 May;15(6):592-600; doi: 10.1016/S1470-2045(14)70129-9. [Epub 2014 Apr 14]Donald Trump
Urologic Oncology|May 3, 2015
Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literatureGeorg A Bjarnason, Bishoy Khalil, John M Hudson, et al.
Pageof 488